Review

Effects of Various Antihypertensive Drugs on Arterial Stiffness and Wave Reflections

Ming Liu Ge-Le Li Yan Li Ji-Guang Wang

Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Key Words

Antihypertensive drugs · Arterial stiffness · Wave reflections · Randomized controlled trial

Abstract

We reviewed trials that tested the efficacy of antihypertensive drugs in reducing arterial stiffness and wave reflections as assessed by pulse wave velocity and augmentation index, respectively. Regardless of cross-over or parallel-group comparison design, placebo-controlled trials demonstrated that antihypertensive drugs were effective in reducing pulse wave velocity. In actively-controlled parallel-group comparison studies, this effect on arterial stiffness was more evident for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers than other classes of antihypertensive drugs, particularly when brachial-ankle pulse wave velocity was measured. Regardless of cross-over or parallel-group comparison or placebo- or actively-controlled design, the reviewed trials showed that β -blockers were inferior to all the other classes of antihypertensive drugs in reducing augmentation index. However, these studies had a small sample size and a short follow-up time and did not link the changes in measurements of arterial function with cardiovascular events. Whether the superiority or inferiority is clinically relevant for cardiovascular protection and prevention remains to be investigated.

© 2013 S. Karger AG, Basel

Introduction

In the past 2 decades, noninvasive measurements of arterial function are increasingly used as an intermediate measure of cardiovascular disease risk in therapeutic trials, such as antihypertensive therapy. Among various parameters of arterial function, pulse wave velocity and augmentation index measure arterial stiffness and wave reflections, respectively. Both

Ji-Guang Wang, MD, PhD
The Shanghai Institute of Hypertension
Ruijin 2nd Road 197
Shanghai 200025 (China)
E-Mail jiguangwang@aim.com

measures can be accurately estimated within minutes with easy-to-use devices and may predict cardiovascular events above and beyond conventional cardiovascular risk factors, such as high blood pressure [1, 2]. However, at present, there is no specific treatment for increased arterial stiffness or wave reflections. Nonetheless, antihypertensive drugs, especially those of vasodilating action, seem to be promising in this regard.

Since the early 1990s, several randomized controlled trials have been conducted to study the effects of various antihypertensive drugs on carotid-femoral or brachial-ankle pulse wave velocity and augmentation index. In the present review article, we summarized these trials to investigate whether and which antihypertensive drugs are efficacious in reducing arterial stiffness and wave reflections and to explore the clinical relevance of these arterial measurements for cardiovascular protection and prevention.

Arterial Effects of Antihypertensive Drugs in Placebo-Controlled Trials

Of the 27 placebo-controlled trials, 11 had a cross-over design (table 1) [3–13] and 16 had a parallel-group comparison design (table 2) [14–29]. Regardless of the design, these placebo-controlled studies had a sample size of tens and a follow-up time of weeks.

Of the 11 placebo-controlled cross-over trials, 6 and 5 had single [8–13] and multiple comparisons with placebo [3–7], respectively, and 2, 4, and 5 studied pulse wave velocity [11, 13], augmentation index alone [4, 5, 7, 10], and both [3, 6, 8, 9, 12], respectively (table 1). The results of these trials were generally consistent across various classes of antihypertensive drugs for pulse wave velocity but not augmentation index. Antihypertensive drugs were efficacious in reducing pulse wave velocity. However, most drugs had neutral effects on augmentation index, and β -blockers even had worse effects than placebo on this measure of wave reflections [6, 12].

Of the 16 placebo-controlled parallel-group comparison trials, 12 and 4 had single [15, 17–22, 24, 25, 27–29] and multiple comparisons with placebo [14, 16, 23, 26], respectively, and 8, 3, and 5 studied pulse wave velocity [14, 16, 19, 24–28], augmentation index alone [15, 18, 23], and both [17, 20–22, 29], respectively (table 2). The results of these parallel-group comparison trials were confirmatory for pulse wave velocity. Antihypertensive drugs significantly reduced pulse wave velocity in 10 of 18 drug comparisons from 13 trials. However, the results of these trials were slightly different for augmentation index. Antihypertensive drugs significantly reduced pulse wave velocity in 4 of 10 drug comparisons from 8 trials, none of which used β -blockers.

Arterial Effects of Antihypertensive Drugs in Actively-Controlled Trials

The actively-controlled trials also included those studies involving 2 or more drug comparisons with placebo. Of the 15 trials with a cross-over design (table 3) [1–5, 10, 30–38] and 31 trials with a parallel-group comparison design (table 4) [13, 16, 23, 26, 39–65], 6 [1–5, 10] and 4 [13, 16, 23, 26], respectively, were part of placebo-controlled studies. These actively-controlled studies also had a small sample size and short follow-up time with the exception of the CAFE ($n = 2,073$) [61], EXPLORE ($n = 331$) [50], and REASON trials ($n = 406$) [65]. These bigger studies investigated combination therapy and (except REASON [65]) had an open design, and hence had limited information on the comparison between drug classes.

Of the cross-over trials, 2, 7, and 6 studied pulse wave velocity [31, 37], augmentation index alone [2, 3, 5, 32, 33, 36, 38], and both [1, 4, 10, 30, 34, 35], respectively (table 3). These trials included 15 comparisons of angiotensin-converting enzyme (ACE) inhibitors with

Table 1. Randomized placebo-controlled double-blind cross-over studies

First author [Ref.]	Year	Subjects	Patients, n	Antihypertensive treatment(s)	Results	
					arterial stiffness	wave reflections
<i>ACEIs</i>						
Pannier [3]	2001	EH	20	perindopril	AUC cfPWV NS	AUC AIx perindopril better
Deary [4]	2002	EH	30	lisinopril	not measured	AIx NS
Morgan [5]	2004	EH	32	ACEIs	not measured	AIx NS
Hirata [6]	2005	CAD	30	ramipril	cfPWV ramipril better	AIx and AIx@HR75 ramipril better
Turner [7]	2006	intracranial aneurysms	19	perindopril	not measured	AIx NS
<i>ARBs</i>						
Asmar [8]	2002	EH/DM	20	telmisartan	cfPWV telmisartan better	AIx NS
Rajagopalan [9]	2006	healthy volunteers	33	valsartan	cfPWV NS	AIx NS
Turner [7]	2006	intracranial aneurysms	19	irbesartan	not measured	AIx NS
Kaufman [10]	2010	EH	10	losartan	not measured	AIx NS
<i>β-Blockers</i>						
Asmar [11]	1991	EH	14	bisoprolol	cfPWV bisoprolol better	not measured
Pannier [3]	2001	EH	20	atenolol	AUC cfPWV atenolol better	AUC AIx NS
Deary [4]	2002	EH	30	bisoprolol	not measured	AIx bisoprolol better
Morgan [5]	2004	EH	32	β-blockers	not measured	AIx NS
Hirata [6]	2005	CAD	30	atenolol	cfPWV atenolol better	AIx atenolol worse; AIx@HR75 NS
Dhakam [12]	2008	EH	16	nebivolol atenolol	aPWV nebivolol better aPWV atenolol better	AIx nebivolol worse AIx atenolol worse
<i>CCBs</i>						
Deary [4]	2002	EH	30	amlodipine	not measured	AIx NS
Morgan [5]	2004	EH	32	CCBs	not measured	AIx NS
<i>Diuretics</i>						
Deary [4]	2002	EH	30	bendrofluazide	not measured	AIx NS
Morgan [5]	2004	EH	32	diuretics	not measured	AIx NS
Davies [13]	2005	EH/DM	10	spironolactone	crPWV spironolactone better	not measured

ACEIs = ACE inhibitors; AIx = augmentation index; AIx@HR75 = AIx corrected for heart rate of 75 beats/min; aPWV = aortic pulse wave velocity; AUC = area under the curve; CAD = coronary artery disease; cfPWV = carotid-femoral pulse wave velocity; crPWV = carotid-radial pulse wave velocity; DM = diabetes mellitus; EH = essential hypertension; NS = not significantly different.

angiotensin receptor blockers (ARBs; n = 3) [5, 30, 31], β-blockers (n = 7) [1–4, 32–34], calcium channel blockers (CCBs; n = 3) [2, 3, 33], and diuretics (n = 2) [2, 3], 2 comparisons of ARBs with β-blockers [35, 36], 6 comparisons between 2 different β-blockers (n = 1) [10] or of β-blockers with CCBs (n = 3) [2, 3, 33] and diuretics (n = 2) [2, 3], 3 comparisons of CCBs with diuretics [2, 3, 37], and 2 comparisons of combination therapy with each of their component drugs [30, 38]. In these short-term cross-over studies, antihypertensive drugs had similar arterial effects, except that β-blockers were inferior to the other classes of antihypertensive drugs in reducing augmentation index in 11 of 14 comparisons with ACE inhibitors, ARBs, CCBs, or diuretics.

Of the parallel group trials, 20, 4, and 7 studied pulse wave velocity [13, 16, 26, 39–43, 46, 47, 49, 52–56, 58–60, 62], augmentation index alone [23, 48, 57, 63], and both [44, 45, 50, 51, 61, 64, 65], respectively (table 4). These trials included 20 comparisons of ACE inhibitors with ARBs (n = 6) [16, 39–43], β-blockers (n = 2) [13, 44], CCBs (n = 8) [13, 39, 40, 43–46], and diuretics (n = 4) [44, 47–49], 13 comparisons of ARBs with β-blockers (n = 2) [50, 51],

Table 2. Randomized placebo-controlled parallel-group comparison studies

First author [Ref.]	Year	De- sign	Subjects	Patients, n	Antihypertensive treatment(s)	Results	
						arterial stiffness	wave reflections
<i>ACEIs</i>							
Kahonen [14]	1998	DB	healthy volunteers	15	captopril	cfPWV captopril better	not measured
Dart [15]	2001	open	EH	111	perindopril	not measured	Alx NS
Ichihara [16]	2005	–	hemodialysis patients	42	trandolapril	baPWV trandolapril better	not measured
Yu [17]	2006	DB	hemodialysis patients	46	ramipril	cfPWV NS	Alx NS
Tsang [18]	2006	DB	IDD	21	quinapril	not measured	Alx NS
Ahimastos [19]	2007	DB	Marfan syndrome	17	perindopril	cfPWV and faPWV perindopril better	not measured
Rahman [20]	2007	DB	DM	21	ramipril	cfPWV NS	Alx NS
			IGT	19	ramipril	cfPWV NS	Alx ramipril better
Mitchell [21]	2007	open	CAD	300	trandolapril	cfPWV trandolapril better	Alx NS
Ahimastos [22]	2008	DB	PAD	40	ramipril	cfPWV ramipril better	Alx ramipril better
<i>ARBs</i>							
Klingbeil [23]	2002	DB	EH	40	valsartan	not measured	Alx valsartan better
Ichihara [16]	2005	–	hemodialysis patients	43	losartan	baPWV NS	not measured
Mitsuhashi [24]	2009	–	EH/hemodialysis patients	40	losartan	baPWV NS	not measured
<i>β-Blockers</i>							
Kahonen [14]	1998	DB	healthy volunteers	15	propranolol	cfPWV propranolol better	not measured
Kahonen [25]	2000	DB	healthy volunteers	31	bisoprolol, celiprolol, and propranolol	cfPWV bisoprolol and propranolol better; celiprolol worse	not measured
Ylitalo [26]	2005	DB	healthy volunteers	18	bisoprolol	cfPWV NS	not measured
<i>CCBs</i>							
London [27]	1990	DB	ESRD	37	nitrendipine	cfPWV nitrendipine better	not measured
Asmar [28]	1992	DB	EH	17	nitrendipine	cfPWV nitrendipine better	not measured
Kahonen [14]	1998	DB	healthy volunteers	15	verapamil	cfPWV NS	not measured
Ylitalo [26]	2005	DB	healthy volunteers	17	nisoldipine	cfPWV NS	not measured
<i>Diuretics</i>							
Klingbeil [23]	2002	DB	EH	40	hydrochlorothi- azide	not measured	Alx NS
Edwards [29]	2009	DB	CKD	112	spironolactone	cfPWV spironolactone better	Alx spironolactone better

ACEIs = ACE inhibitors; Alx = augmentation index; baPWV = brachial-ankle pulse wave velocity; CAD = coronary artery disease; cfPWV = carotid-femoral pulse wave velocity; CKD = chronic kidney disease; DB = double-blinded; DM = diabetes mellitus; EH = essential hypertension; ESRD = end-stage renal dysfunction; faPWV = femoral-dorsalis pedis pulse wave velocity; IDD = isolated diastolic dysfunction; IGT = impaired glucose tolerance; NS = not significantly different; PAD = peripheral artery disease.

CCBs (n = 10) [39, 40, 43, 52–58], or a diuretic (n = 1) [23], 5 comparisons of β-blockers with CCBs (n = 4) [13, 26, 44, 59] or a diuretic (n = 1) [44], 7 comparisons between 2 different CCBs (n = 1) [40] or of CCBs with diuretics (n = 6) [44, 60–64], and 2 comparisons of combination therapy with one [65] or two of their component drugs [41]. In these studies, ACE inhibitors or ARBs tended to be more efficacious than other classes of antihypertensive drugs in reducing arterial stiffness, especially when brachial-ankle pulse wave velocity was measured in 11 trials [16, 40, 41, 43, 46, 52–54, 56, 58, 62]. The results were not consistent for other comparisons of pulse wave velocity or for studies on augmentation index, except that β-blockers were inferior to the other classes of antihypertensive drugs in reducing augmentation index in all 5 comparisons with an ACE inhibitor (n = 1) [44], ARBs (n = 2) [50, 51], a CCB (n = 1) [44], or a diuretic (n = 1) [44].

Table 3. Randomized actively-controlled cross-over studies

First author [Ref.]	Year	De- sign	Subjects	Patients, n	Comparison(s)	Results	
						arterial stiffness	wave reflections
ACEIs							
<i>vs. ARBs</i>							
Mahmud [30]	2002	SB	EH	12	captopril vs. valsartan	cfPWV NS	Alx NS
Turner [7]	2006	DB	intracranial aneurysms	19	perindopril vs. irbesartan	not measured	Alx NS
Ali [31]	2009	DB	EH	15	lisinopril vs. irbesartan	cfPWV NS	not measured
<i>vs. β-blockers</i>							
Chen [32]	1995	DB	EH	79	fosinopril vs. atenolol	not measured	Alx fosinopril better
Pannier [3]	2001	DB	EH	20	perindopril vs. atenolol	cfPWV atenolol better	AUC Alx peri- dopril better
Deary [4]	2002	DB	EH	30	lisinopril vs. bisoprolol	not measured	Alx lisinopril better
Morgan [5]	2004	DB	EH	32	ACEIs vs. β -blockers	not measured	Alx ACEIs better
Neal [33]	2004	DB	EH/liver transplan- tation	12	lisinopril vs. bisoprolol	not measured	Alx lisinopril better
Hirata [6]	2005	DB	CAD	30	ramipril vs. atenolol	cfPWV NS	Alx and Alx@HR75 ramipril better
Kaiser [34]	2006	DB	EH/DM	10	enalapril vs. nebivolol	cfPWV NS	Alx NS
<i>vs. CCBs</i>							
Deary [4]	2002	DB	EH	30	lisinopril vs. amlodipine	not measured	Alx NS
Morgan [5]	2004	DB	EH	32	ACEIs vs. CCBs	not measured	Alx NS
Neal [33]	2004	DB	EH/liver transplan- tation	12	lisinopril vs. amlodipine	not measured	Alx NS
<i>vs. diuretics</i>							
Deary [4]	2002	DB	EH	30	lisinopril vs. bendrofluazide	not measured	Alx NS
Morgan [5]	2004	DB	EH	32	ACEIs vs. diuretics	not measured	Alx NS
ARBs							
<i>vs. β-blockers</i>							
Dhakam [35]	2006	DB	EH	21	eprosartan vs. atenolol	cfPWV atenolol better	Alx eprosartan better
Izzo [36]	2012	SB	EH	30	lisinopril + valsartan vs. lisinopril + carvedilol	not measured	Alx NS
β-Blockers							
<i>vs. β-blockers</i>							
Dhakam [12]	2008	DB	EH	16	atenolol vs. nebivolol	aPWV NS	Alx nebivolol better
<i>vs. CCBs</i>							
Deary [4]	2002	DB	EH	30	bisoprolol vs. amlodipine	not measured	Alx amlodipine better
Morgan [5]	2004	DB	EH	32	β -blockers vs. CCBs	not measured	Alx CCBs better
Neal [33]	2004	DB	EH/liver transplan- tation	12	bisoprolol vs. amlodipine	not measured	Alx NS
<i>vs. diuretics</i>							
Deary [4]	2002	DB	EH	30	bisoprolol vs. bendrofluazide	not measured	Alx bendro- fluazide better
Morgan [5]	2004	DB	EH	32	β -blockers vs. diuretics	not measured	Alx diuretics better

Table 3 (continued)

First author [Ref.]	Year	De- sign	Subjects	Patients, n	Comparison(s)	Results	
						arterial stiffness	wave reflections
CCBs							
<i>vs. diuretics</i>							
Asmar [37]	1993	DB	EH	16	felodipine vs. hydrochloro- thiazide	cfPWV felodipine better	not measured
Deary [4]	2002	DB	EH	30	amlodipine vs. bendrofluazide	not measured	AIx NS
Morgan [5]	2004	DB	EH	32	CCBs vs. diuretics	not measured	AIx NS
Other							
Mahmud [30]	2002	SB	EH	12	captopril + valsartan vs. captopril vs. valsartan	cfPWV combination better	AIx combination better
Ferguson [38]	2008	DB	EH	22	fosinopril + hydrochloro- thiazide vs. amlodipine vs. indapamide	not measured	AIx combination better

ACEIs = ACE inhibitors; AIx = augmentation index; AIx@HR75 = AIx corrected for heart rate of 75 beats/min; aPWV = aortic pulse wave velocity; AUC = area under the curve; CAD = coronary artery disease; cfPWV = carotid-femoral pulse wave velocity; DB = double-blinded; DM = diabetes mellitus; EH = essential hypertension; NS = not significantly different; SB = single-blinded.

Conclusions and Perspectives

Our narrative review was informative on three clinically relevant questions. First, anti-hypertensive drugs are effective in reducing arterial stiffness. However, this effect does not at all infer any benefit above and beyond blood pressure lowering. In contrast, because pulse wave velocity is dependent on systolic blood pressure, the therapeutic effect of antihypertensive drugs on arterial stiffness, to some extent if not entirely, can be attributable to their blood pressure lowering efficacy. Second, though all antihypertensive drugs reduce arterial stiffness, ACE inhibitors or ARBs might be more efficacious than other classes of antihypertensive drugs. This effect is more evident when brachial-ankle pulse wave velocity is measured. The mechanism remains to be elucidated. Third, as also evidenced by a recent meta-analysis of randomized controlled trials that compared β -blockers with the other classes of antihypertensive drugs [66], because of the intrinsic heart rate slowing effect, β -blockers are inferior to all the other classes of antihypertensive drugs in reducing augmentation index. However, whether this inferiority is clinically relevant for cardiovascular protection and prevention remains to be investigated.

In spite of a large number of trials that studied the efficacy of antihypertensive drugs in reducing pulse wave velocity and augmentation index, these studies had a small sample size and a short follow-up time and did not link the changes in measurements of arterial function with cardiovascular events. It is therefore imperative to combine the research force in the field of arterial functions to run adequately powered outcome trials to investigate whether arterial stiffness and wave reflections are clinically useful in monitoring the effect of antihypertensive treatment and other cardiovascular therapeutic approaches.

Table 4. Randomized actively-controlled parallel-group comparison studies

First author	Year	De- sign	Subjects	Patients, n	Comparison(s)	Results	
						arterial stiffness	wave reflections
ACEIs							
<i>vs. ARBs</i>							
Rajzer [39]	2003	open	EH	62	quinapril vs. losartan	cfPWV quinapril better	not measured
Takami [40]	2003	SB	EH	40	temocapril vs. valsartan	baPWV valsartan better	not measured
Ichihara [16]	2005	SB	hemodialysis patients	43	trandolapril vs. losartan	baPWV NS	not measured
Anan [41]	2005	SB	EH	21	perindopril vs. valsartan	baPWV NS	not measured
Rehman [42]	2007	DB	EH	39	perindopril vs. losartan	cfPWV NS	not measured
Li [43]	2009	SB	EH	68	perindopril vs. telmisartan	baPWV telmisartan better	not measured
<i>vs. β-blockers</i>							
Kahonen [14]	1998	DB	healthy volunteers	15	captopril vs. propranolol	aPWV NS	not measured
Mackenzie [44]	2009	DB	EH	32	perindopril vs. atenolol	cfPWV NS	Alx perindopril better
<i>vs. CCBs</i>							
London [45]	1994	SB	ESRD	24	perindopril vs. nitrendipine	cfPWV NS	Alx NS
Kahonen [14]	1998	DB	healthy volunteers	15	captopril vs. verapamil	aPWV NS	not measured
Rajzer [39]	2003	open	EH	75	quinapril vs. amlodipine	cfPWV quinapril better	not measured
Takami [40]	2003	–	EH	40	temocapril vs. cilnidipine	baPWV NS	not measured
				36	temocapril vs. nifedipine	baPWV temocapril better	not measured
Morimoto [46]	2008	–	EH	32	ARB + perindopril vs. ARB + amlodipine	baPWV NS	not measured
Mackenzie [44]	2009	DB	EH	29	perindopril vs. lercanidipine	cfPWV NS	Alx NS
Li [43]	2009	SB	EH	68	perindopril vs. amlodipine	baPWV amlodipine better	not measured
<i>vs. diuretics</i>							
Breithaupt-Grogler [47]	1996	DB	EH	17	cilazapril vs. hydrochlorothiazide	cfPWV NS	not measured
Jiang [48]	2005	DB	EH	101	enalapril vs. indapamide	not measured	Alx enalapril better
Mackenzie [44]	2009	DB	EH	28	perindopril vs. bendrofluazide	cfPWV NS	Alx NS
Kostka-Jeziorny [49]	2011	open	EH	66	perindopril vs. hydrochlorothiazide	cfPWV NS	not measured
ARBs							
<i>vs. β-blockers</i>							
Boutouyrie [50]	2010	open	EH	331	amlodipine + valsartan vs. amlodipine + atenolol	cfPWV NS	Alx and Alx@HR75 valsartan better
Vitale [51]	2012	DB	EH	65	irbesartan vs. nebivolol	cfPWV NS	Alx irbesartan better; Alx@HR75 NS
<i>vs. CCBs</i>							
Rajzer [39]	2003	open	EH	61	losartan vs. amlodipine	cfPWV NS	not measured
Takami [40]	2003	–	EH	40	valsartan vs. cilnidipine vs. nifedipine	baPWV valsartan better	not measured
Munakata [52]	2004	–	EH	41	valsartan vs. nifedipine	baPWV valsartan better	not measured
Ichihara [53]	2006	–	EH	100	valsartan vs. amlodipine	baPWV NS	not measured
Morimoto [54]	2006	–	EH	43	telmisartan vs. amlodipine	baPWV telmisartan better	not measured
Kosch [55]	2008	DB	EH	52	valsartan vs. metoprolol	cfPWV NS	not measured
Ishii [56]	2008	–	EH/DM	22	candesartan vs. CCBs	baPWV candesartan better	not measured
Schneider [57]	2008	DB	EH	156	irbesartan vs. atenolol	not measured	Alx irbesartan better
Li [43]	2009	SB	EH	68	telmisartan vs. amlodipine	baPWV telmisartan better	not measured
Tomiyama [58]	2011	–	EH	113	candesartan vs. amlodipine	baPWV candesartan better	not measured

Table 4 (continued)

First author	Year	De- sign	Subjects	Patients, n	Comparison(s)	Results	
						arterial stiffness	wave reflections
<i>vs. diuretics</i>							
Klingbeil [23]	2002	DB	EH	40	valsartan vs. hydrochlorothiazide	not measured	Alx valsartan better
β-Blockers							
<i>vs. CCBs</i>							
Merli [59]	1993	DB	EH	28	metoprolol vs. isradipine	cfPWV isradipine better	not measured
Kahonen [14]	1998	DB	healthy volunteers	15	propranolol vs. verapamil	cfPWV propranolol better	not measured
Ylitalo [26]	2005	DB	healthy volunteers	18	bisoprolol vs. nisoldipine	cfPWV NS	not measured
Mackenzie [44]	2009	DB	EH	31	atenolol vs. lercanidipine	cfPWV NS	Alx lercanidipine better
<i>vs. diuretics</i>							
Mackenzie [44]	2009	DB	EH	30	atenolol vs. bendrofluazide	cfPWV NS	Alx bendrofluazide better
CCBs							
<i>vs. CCBs</i>							
Takami [40]	2003	–	EH	36	cilnidipine vs. nifedipine	baPWV cilnidipine better	not measured
<i>vs. diuretics</i>							
White [60]	2003	DB	EH	139	amlodipine vs. eplerenone	cfPWV NS	not measured
Williams [61]	2006	open	EH	2,073	amlodipine vs. atenolol	cfPWV NS (n = 114)	Alx amlodipine better
Kaneshiro [62]	2009	DB	CKD	68	valsartan + amlodipine vs. valsartan + thiazide	baPWV NS	not measured
Mackenzie [44]	2009	DB	EH	27	lercanidipine vs. bendrofluazide	cfPWV NS	Alx NS
Doi [63]	2010	open	EH	37	azelnidipine vs. trichlormethiazide	not measured	Alx and Alx@HR75 azelnidipine better
Matsui [64]	2011	open	EH	207	azelnidipine vs. hydrochlorothiazide	cfPWV azelnidipine better	Alx NS
Other							
Asmar [65]	2001	DB	EH	406	perindopril + indapamide vs. atenolol	cfPWV NS	Alx combination better
Anan [41]	2005	–	EH	21	perindopril + valsartan vs. perindopril vs. valsartan	baPWV combination better	not measured

ACEIs = ACE inhibitors; Alx = augmentation index; Alx@HR75 = Alx corrected for heart rate of 75 beats/min; aPWV = aortic pulse wave velocity; baPWV = brachial-ankle pulse wave velocity; cfPWV = carotid-femoral pulse wave velocity; CKD = chronic kidney disease; DB = double-blinded; DM = diabetes mellitus; EH = essential hypertension; ESRD = end-stage renal dysfunction; NS = not significantly different; SB = single-blinded.

Acknowledgement

The authors were financially supported by grants from the National Natural Science Foundation of China (grants 30871360, 30871081, 81170245, and 81270373), the Ministry of Science and Technology (a grant for China-European Union collaborations, 1012), and the Ministry of Education (NCET-09-0544), Beijing, China, the Shanghai Commissions of Science and Technology (grant 07JC14047, the 'Rising Star' program 06QA14043, and 11QH1402000) and Education (grant 07ZZ32 and the 'Dawn' project 08SG20), the Shanghai Bureau of Health (XBR2011004), Shanghai Jiaotong University School of Medicine (a grant of Distinguished Young Investigators to Y.L.), and the European Union (grants LSHM-CT-2006-037093 and HEALTH-F4-2007-201550).

Disclosure Statement

J.-G.W. reports receiving lecture and consulting fees from A&D, Boehringer-Ingelheim, MSD, Novartis, Omron, Pfizer, Servier, and Takeda.

References

- 1 Vlachopoulos C, Aznaouridis K, Stefanadis C: Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J Am Coll Cardiol* 2010;55:1318–1327.
- 2 Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C: Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. *Eur Heart J* 2010;31:1865–1871.
- 3 Pannier BM, Guerin AP, Marchais SJ, London GM: Different aortic reflection wave responses following long-term angiotensin-converting enzyme inhibition and beta-blocker in essential hypertension. *Clin Exp Pharmacol Physiol* 2001;28:1074–1077.
- 4 Deary AJ, Schumann AL, Murfet H, Haydock S, Foo RS, Brown MJ: Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. *Clin Sci (Lond)* 2002;103:493–499.
- 5 Morgan T, Lauri J, Bertram D, Anderson A: Effect of different antihypertensive drug classes on central aortic pressure. *Am J Hypertens* 2004;17:118–123.
- 6 Hirata K, Vlachopoulos C, Adji A, O'Rourke MF: Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? *J Hypertens* 2005;23:551–556.
- 7 Turner CL, Wilkinson IB, Kirkpatrick PJ: Use of antihypertension agents for the suppression of arterial pulse pressure waveforms in patients with intracranial aneurysms. *J Neurosurg* 2006;104:531–536.
- 8 Asmar R, Gosse P, Topouchian J, N'Tela G, Dudley A, Shepherd GL: Effects of telmisartan on arterial stiffness in type 2 diabetes patients with essential hypertension. *J Renin Angiotensin Aldosterone Syst* 2002;3:176–180.
- 9 Rajagopalan S, Kariisa M, Dellegrottaglie S, Bard RL, Kehrer C, Matlow S, Daley W, Pitt B, Brook R: Angiotensin receptor blockade improves vascular compliance in healthy normotensive elderly individuals: results from a randomized double-blind placebo-controlled trial. *J Clin Hypertens (Greenwich)* 2006;8:783–790.
- 10 Kaufman R, Nunes I, Bolognese JA, Miller DL, Salotti D, McCarthy JM, Smith WB, Herman GA, Feig PU: Single-dose effects of isosorbidedemonitrate alone or in combination with losartan on central blood pressure. *J Am Soc Hypertens* 2010;4:311–318.
- 11 Asmar RG, Keriuel JC, Girerd XJ, Safar ME: Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. *Am J Cardiol* 1991;68:61–64.
- 12 Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB: A comparison of atenolol and nebivolol in isolated systolic hypertension. *J Hypertens* 2008;26:351–356.
- 13 Davies J, Gavin A, Band M, Morris A, Struthers A: Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients. *Br J Clin Pharmacol* 2005;59:520–523.
- 14 Kahonen M, Ylitalo R, Koobi T, Turjanmaa V, Ylitalo P: Influence of captopril, propranolol, and verapamil on arterial pulse wave velocity and other cardiovascular parameters in healthy volunteers. *Int J Clin Pharmacol Ther* 1998;36:483–489.
- 15 Dart AM, Reid CM, McGrath B: Effects of ACE inhibitor therapy on derived central arterial waveforms in hypertension. *Am J Hypertens* 2001;14:804–810.
- 16 Ichihara A, Hayashi M, Kaneshiro Y, Takemitsu T, Homma K, Kanno Y, Yoshizawa M, Furukawa T, Takenaka T, Saruta T: Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. *Am J Kidney Dis* 2005;45:866–874.
- 17 Yu WC, Lin YP, Lin IF, Chuang SY, Chen CH: Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. *Am J Kidney Dis* 2006;47:478–484.
- 18 Tsang TS, Barnes ME, Abhayaratna WP, Cha SS, Gersh BJ, Langins AP, Green TD, Bailey KR, Miyasaka Y, Seward JB: Effects of quinapril on left atrial structural remodeling and arterial stiffness. *Am J Cardiol* 2006;97:916–920.
- 19 Ahimastos AA, Aggarwal A, D'Orsa KM, Formosa MF, White AJ, Savarirayan R, Dart AM, Kingwell BA: Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. *JAMA* 2007;298:1539–1547.
- 20 Rahman S, Ismail AA, Ismail SB, Naing NN, Abdul RA: Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study. *Eur J Clin Pharmacol* 2007;63:733–741.
- 21 Mitchell GF, Dunlap ME, Warnica W, Ducharme A, Arnold JM, Tardif JC, Solomon SD, Domanski MJ, Jablonski KA, Rice MM, Pfeffer MA: Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. *Hypertension* 2007;49:1271–1277.

- 22 Ahimastos AA, Dart AM, Lawler A, Blombery PA, Kingwell BA: Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. *J Hypertens* 2008;26:1037–1042.
- 23 Klingbeil AU, John S, Schneider MP, Jacobi J, Weidinger G, Schmieder RE: AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study. *J Hypertens* 2002;20:2423–2428.
- 24 Mitsuhashi H, Tamura K, Yamauchi J, Ozawa M, Yanagi M, Dejima T, Wakui H, Masuda S, Azuma K, Kanaoka T, Ohsawa M, Maeda A, Tsurumi-Ikeya Y, Okano Y, Ishigami T, Toya Y, Tokita Y, Ohnishi T, Umemura S: Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. *Atherosclerosis* 2009;207:186–190.
- 25 Kahonen M, Ylitalo R, Koobi T, Turjanmaa V, Ylitalo P: Influences of nonselective, beta(1)-selective and vasodilatory beta(1)-selective beta-blockers on arterial pulse wave velocity in normotensive subjects. *Gen Pharmacol* 2000;35:219–224.
- 26 Ylitalo R, Kahonen M, Nieminen T, Koobi T, Ylitalo P, Turjanmaa V: Effects of a mononitrate, a beta1-blocker and a dihydropyridine calcium channel blocker on cardiovascular responsiveness to passive orthostasis: a placebo-controlled double-blind study in normotensive volunteers. *Arzneimittelforschung* 2005;55:160–166.
- 27 London GM, Marchais SJ, Guerin AP, Metivier F, Safar ME, Fabiani F, Froment L: Salt and water retention and calcium blockade in uremia. *Circulation* 1990;82:105–113.
- 28 Asmar R, Benetos A, Brahim M, Chouche K, Safar M: Arterial and antihypertensive effects of nitrendipine: a double-blind comparison versus placebo. *J Cardiovasc Pharmacol* 1992;20:858–863.
- 29 Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN: Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. *J Am Coll Cardiol* 2009;54:505–512.
- 30 Mahmud A, Feely J: Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. *Am J Hypertens* 2002;15:321–325.
- 31 Ali K, Rajkumar C, Fantin F, Schiff R, Bulpitt CJ: Irbesartan improves arterial compliance more than lisinopril. *Vasc Health Risk Manag* 2009;5:587–592.
- 32 Chen CH, Ting CT, Lin SJ, Hsu TL, Yin FC, Siu CO, Chou P, Wang SP, Chang MS: Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. *Hypertension* 1995;25:1034–1041.
- 33 Neal DA, Brown MJ, Wilkinson IB, Byrne CD, Alexander GJ: Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. *Transplantation* 2004;77:748–750.
- 34 Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT: Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. *J Hypertens* 2006;24:1397–1403.
- 35 Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB: Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. *Am J Hypertens* 2006;19:214–219.
- 36 Izzo JJ, Rajpal M, Karan S, Srikakarlaludi S, Osmond PJ: Hemodynamic and central blood pressure differences between carvedilol and valsartan added to lisinopril at rest and during exercise stress. *J Am Soc Hypertens* 2012;6:117–123.
- 37 Asmar RG, Benetos A, Chouche-Teyara K, Raveau-Landon CM, Safar ME: Comparison of effects of felodipine versus hydrochlorothiazide on arterial diameter and pulse-wave velocity in essential hypertension. *Am J Cardiol* 1993;72:794–798.
- 38 Ferguson JM, Minas J, Siapantas S, Komesaroff PA, Sudhir K: Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension. *J Cardiovasc Pharmacol* 2008;51:590–595.
- 39 Rajzer M, Kloczek M, Kawecka-Jaszcz K: Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. *Am J Hypertens* 2003;16:439–444.
- 40 Takami T, Shigemasa M: Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. *Hypertens Res* 2003;26:609–614.
- 41 Anan F, Takahashi N, Ooie T, Yufu K, Hara M, Nakagawa M, Yonemochi H, Saikawa T, Yoshimatsu H: Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. *Eur J Clin Pharmacol* 2005;61:353–359.
- 42 Rehman A, Ismail SB, Naing L, Roshan TM, Rahman AR: Reduction in arterial stiffness with angiotensin II antagonism and converting enzyme inhibition. A comparative study among Malay hypertensive subjects with a known genetic profile. *Am J Hypertens* 2007;20:184–189.
- 43 Li Y, Ma SM, Du M, Chu WW, Cheng XM: Perindopril, amlodipine and telmisartan improve arterial stiffness in patients with hypertension (in Chinese). *Zhonghua Xin Xue Guan Bing Za Zhi* 2009;37:908–912.
- 44 Mackenzie IS, McEniery CM, Dhakam Z, Brown MJ, Cockcroft JR, Wilkinson IB: Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. *Hypertension* 2009;54:409–413.
- 45 London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL: Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. *Circulation* 1994;90:2786–2796.
- 46 Morimoto S, Maki K, Aota Y, Sakuma T, Iwasaka T: Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function. *Hypertens Res* 2008;31:1603–1610.

- 47 Breithaupt-Grogler K, Leschinger M, Belz GG, Butzer R, Erb K, de May C, Sinn W: Influence of antihypertensive therapy with cilazapril and hydrochlorothiazide on the stiffness of the aorta. *Cardiovasc Drugs Ther* 1996;10:49–57.
- 48 Jiang XJ, Li QY, Zhang YQ, Liu GZ, Liu LS: The comparison of the effect of enalapril and indapamide on the peripheral blood pressure and central blood pressure through pulse wave analysis (in Chinese). *Zhonghua Xin Xue Guan Bing Za Zhi* 2005;33:885–888.
- 49 Kostka-Jeziorny K, Uruski P, Tykarski A: Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. *Blood Press* 2011;20:104–110.
- 50 Boutouyrie P, Achouba A, Trunet P, Laurent S: Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. *Hypertension* 2010;55:1314–1322.
- 51 Vitale C, Marazzi G, Iellamo F, Spoletini I, Dall'Armi V, Fini M, Volterrani M: Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. *Int J Cardiol* 2012;155:279–284.
- 52 Munakata M, Nagasaki A, Nunokawa T, Sakuma T, Kato H, Yoshinaga K, Toyota T: Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. *Am J Hypertens* 2004;17:1050–1055.
- 53 Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M: Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. *J Hum Hypertens* 2006;20:787–794.
- 54 Morimoto S, Yano Y, Maki K, Sawada K: Renal and vascular protective effects of telmisartan in patients with essential hypertension. *Hypertens Res* 2006;29:567–572.
- 55 Kosch M, Levers A, Lang D, Bartels V, Rahn KH, Pavenstadt H, Hausberg M: A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension. *Nephrol Dial Transplant* 2008;23:2280–2285.
- 56 Ishii H, Tsukada T, Yoshida M: Angiotensin II type-I receptor blocker, candesartan, improves brachial-ankle pulse wave velocity independent of its blood pressure lowering effects in type 2 diabetes patients. *Intern Med* 2008;47:2013–2018.
- 57 Schneider MP, Delles C, Klingbeil AU, Ludwig M, Kolloch RE, Krekler M, Stumpe KO, Schmieder RE: Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial. *J Renin Angiotensin Aldosterone Syst* 2008;9:49–56.
- 58 Tomiyama H, Yoshida M, Yamada J, Matsumoto C, Odaira M, Shiina K, Yamashina A: Arterial-cardiac destiffening following long-term antihypertensive treatment. *Am J Hypertens* 2011;24:1080–1086.
- 59 Merli I, Simon A, Del PM, Brautigam M, Welzel D, Levenson J: Intrinsic effect of antihypertensive treatment with isradipine and metoprolol on large artery geometric and elastic properties. *Clin Pharmacol Ther* 1993;54:76–83.
- 60 White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. *Hypertension* 2003;41:1021–1026.
- 61 Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation* 2006;113:1213–1225.
- 62 Kaneshiro Y, Ichihara A, Sakoda M, Kurauchi-Mito A, Kinouchi K, Itoh H: Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan. *Kidney Blood Press Res* 2009;32:51–58.
- 63 Doi M, Miyoshi T, Hirohata S, Kamikawa S, Usui S, Kaji Y, Sakane K, Ogawa H, Ninomiya Y, Kusachi S: Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients. *Am J Med Sci* 2010;339:433–439.
- 64 Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Shimada K, Kario K: Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study. *Atherosclerosis* 2011;215:184–188.
- 65 Asmar RG, London GM, O'Rourke ME, Safar ME: Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. *Hypertension* 2001;38:922–926.
- 66 Ding FH, Li Y, Li LH, Wang JG: Impact of heart rate on central hemodynamics and stroke: a meta-analysis of β -blocker trials. *Am J Hypertens* 2013;26:118–125.